The men and women in this community who get the best results are the ones who treat peptides a precision tool within the confines of a fully optimized system
"By adding PYY to the GLP1/GIP/glucagon trio, we hope to rely less on GLP1 and glucagon to drive weight loss, potentially lowering the chance of nausea (from GLP1/PYY) and high blood sugar risk (from glucagon) while keeping the benefits." The medication is still in the experimental/preclinical stage and has not yet been tested in human trials
The protocol was approved by the National Institutes of Health (NIH) Addictions Institutional Review Board (IRB), FDA, and the Drug Enforcement Administration (DEA), and was registered at ClinicalTrials.gov (NCT02177513)
Zhou M, Mok MT, Sun H, Chan AW, Huang Y, Cheng AS, et al